Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 18;9(7):e70181.
doi: 10.1002/hem3.70181. eCollection 2025 Jul.

Distribution reappraisal of peripheral T- and NK-cell lymphoma entities through the French Lymphopath network database

Thomas Grange  1 , Elsa Poullot  1   2   3 , Marie Parrens  4   5 , Alexandra Traverse-Glehen  6 , Charlotte Syrykh  7   8 , Luc Xerri  9 , Julie Bruneau  10 , Virginie Fataccioli  1   3 , Nadia Amara  7 , Romain Dubois  11 , Anne Moreau  12   13 , Alina Nicolae  14   15 , Fanny Drieux  16 , Vanessa Lacheretz-Szablewski  17 , Francisco Llamas-Gutierrez  18 , Albane Ledoux-Pilon  19 , Marie-Christine Copin  20 , Catherine Chassagne-Clément  21 , François Lemonnier  2   3   22 , Pierre Brousset  7   8 , Philippe Gaulard  1   2   3
Affiliations

Distribution reappraisal of peripheral T- and NK-cell lymphoma entities through the French Lymphopath network database

Thomas Grange et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Romain Dubois reports consulting for AstraZeneca, Recordati Rare Disease, Owkin, Roche, Kyowa Kirin, and Takeda. Philippe Gaulard reports a consulting or advisory role for Takeda, Gilead, and Recordati; research funding from Innate Pharma, Takeda, and Sanofi; and paid travel to meetings from Roche. François Lemonnier reports honoraria from Takeda and AstraZeneca; advisory board for Miltenyi, Kyowa Kirin and BMS; paid travel from Roche, Gilead, AbbVie, and BeiGene; and research funding from BMS and Roche.

Figures

Figure 1
Figure 1
Lymphopath: a national network for expert pathologic review of lymphoma diagnosis. (A) Workflow of the Lymphopath network. FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; ISH, in situ hybridization. (B) Inclusion and exclusion criteria for the current study. PTCL, peripheral T‐cell and NK‐cell Lymphoma. (C) Sankey plot showing the reclassification of PTCL diagnostic categories after review in the Lymphopath network. ALCL, anaplastic large‐cell lymphoma; Int, intestinal lymphoma; NKTCL, extranodal NK‐/T‐cell lymphoma, nasal type; PTCL‐NOS, peripheral T‐cell lymphoma, not otherwise specified; TFHL, nodal T‐follicular helper (TFH) cell lymphoma; T/NK Leuk., mature T‐cell and NK‐cell leukemias; Unc., unclassified.
Figure 2
Figure 2
Pathological landscape of PTCLs in France from 2018 to 2021. (A) Relative frequencies of PTCL subtypes among 2529 noncutaneous PTCLs diagnosed through the Lymphopath network over the 2018–2021 period. ANKL, aggressive NK‐cell leukemia; AITL, angioimmunoblastic T‐cell lymphoma; ALCL, anaplastic large‐cell lymphoma; ALCL‐ALK−, ALCL ALK‐negative; ALCL‐ALK+, ALCL ALK‐positive; ATLL, adult T‐cell leukemia/lymphoma; BIA‐ALCL, breast implant‐associated ALCL; CLPD‐NK, chronic lymphoproliferative disorder of NK cells; Int., intestinal lymphoma; EATL, enteropathy‐associated T‐cell lymphoma; FTCL, follicular T‐cell lymphoma; HSTL, hepatosplenic T‐cell lymphoma; ITCL‐NOS, intestinal T‐cell lymphoma, not otherwise specified; iTLPD‐GI, indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract; Leuk.: Mature T‐cell and NK‐cell leukemias; MEITL, monomorphic epitheliotropic intestinal T‐cell lymphoma; NKTCL, extranodal NK‐/T‐cell lymphoma, nasal type; PTCL‐NOS, peripheral T‐cell lymphoma, not otherwise specified; PTCL‐TFH, nodal peripheral T‐cell lymphoma with TFH phenotype (i.e., TFH lymphoma, NOS); Syst. EBV + TCL, systemic EBV + T‐cell lymphoma of childhood; T‐cell PTLD, T‐cell posttransplant lymphoproliferative disorders; T‐LGLL, T‐cell large granular lymphocytic leukemia; T‐PLL, T‐cell prolymphocytic leukemia; TFHL, nodal T‐follicular helper (TFH) cell lymphoma; Unc., unclassified. (B) Relative frequencies of PTCL diagnostic categories among patients younger than 30 years of age (left), from 30 to 59 years of age (middle), and older than 60 years of age (right).
See this image and copyright information in PMC

References

    1. Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the french lymphopath network. J Clin Oncol. 2017;35(18):2008‐2017. - PubMed
    1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019‐5032. - PMC - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375‐2390. - PMC - PubMed
    1. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229‐1253. - PMC - PubMed
    1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720‐1748. - PMC - PubMed

LinkOut - more resources